Zoetis Inc. $ZTS Shares Acquired by Concurrent Investment Advisors LLC

Key Points

• Concurrent Investment Advisors nearly doubled its Zoetis stake in the second quarter, adding 17,105 shares to own 34,405 shares valued at approximately $2.47 million. Institutional investors collectively hold 92.8% of the company.
• Analyst sentiment is mixed, with Zoetis carrying a consensus “Hold” rating and an average price target of $101.08; several firms recently lowered their targets, though JPMorgan maintained an “overweight” rating.
• Zoetis reported quarterly EPS of $1.87, slightly above estimates, while revenue reached $2.47 billion and declined 0.2% year over year. The stock opened at $73.56, near its 52-week low of $71.00.

Concurrent Investment Advisors LLC increased its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 98.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,405 shares of the company's stock after purchasing an additional 17,105 shares during the quarter. Concurrent Investment Advisors LLC's holdings in Zoetis were worth $2,472,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. NEOS Investment Management LLC grew its holdings in shares of Zoetis by 14.5% during the second quarter. NEOS Investment Management LLC now owns 71,746 shares of the company's stock worth $5,156,000 after buying an additional 9,099 shares in the last quarter. AXQ Capital LP purchased a new position in shares of Zoetis during the second quarter valued at approximately $2,972,000. Continuum Advisory LLC acquired a new stake in Zoetis during the second quarter worth approximately $110,000. Nykredit A S purchased a new stake in Zoetis in the 2nd quarter worth approximately $10,042,000. Finally, InTrack Investment Management Inc grew its stake in Zoetis by 90.3% in the 2nd quarter. InTrack Investment Management Inc now owns 5,373 shares of the company's stock worth $386,000 after acquiring an additional 2,550 shares during the period. Institutional investors and hedge funds own 92.80% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Cantor Fitzgerald set a $94.00 price target on Zoetis in a research note on Tuesday, August 25th. Argus reaffirmed a "hold" rating on shares of Zoetis in a research report on Wednesday, May 27th. BNP Paribas Exane dropped their target price on Zoetis from $146.00 to $110.00 and set an "outperform" rating for the company in a research note on Tuesday, August 11th. Weiss Ratings lowered Zoetis from a "sell (d+)" rating to a "sell (d)" rating in a research note on Friday, June 12th. Finally, JPMorgan Chase & Co. reduced their target price on Zoetis from $130.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $101.08.

Zoetis Stock Performance

NYSE:ZTS opened at $73.56 on Wednesday. The company has a market cap of $30.40 billion, a P/E ratio of 12.12, a P/E/G ratio of 1.77 and a beta of 0.73. The firm's 50 day moving average is $75.61 and its two-hundred day moving average is $92.87. Zoetis Inc. has a fifty-two week low of $71.00 and a fifty-two week high of $152.12. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion during the quarter, compared to analysts' expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business's quarterly revenue was down .2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Analysts expect that Zoetis Inc. will post 6.2 EPS for the current year.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.